Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
02 November 2022 - 07:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2022
Commission File Number: 001-38245
Akso Health Group
(Exact name of registrant as specified in its charter)
Room 515, Floor 5,
Jia No. 92-4 to 24 Jianguo Road
Chaoyang District, Beijing
100020
People's Republic of
China
Tel: +86 10 5370
9902
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(1): ¨
Note : Regulation
S-T Rule 101(b)(1) only permits the submission in
paper of a Form 6-K if submitted solely to provide an attached
annual report to security holders.
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to
furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant’s “home country”), or
under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report
or other document is not a press release, is not required to be and
has not been distributed to the registrant’s security holders, and,
if discussing a material event, has already been the subject of a
Form 6-K submission or other Commission filing on EDGAR.
Change in Registrant’s Certifying Accountant
Previous Independent Registered Public Accounting Firm
On October 12, 2022, the Audit Committee (the “Audit
Committee”) of the Board of Directors of Akso Health Group (the
“Company”) dismissed Wei, Wei & Co., LLP (“WWC”)
as the Company’s independent registered public accounting firm,
effective October 12, 2022.
For the fiscal year ended March 31, 2021, WWC’s audit reports on
the Company’s financial statements did not contain an adverse
opinion or disclaimer of opinion, nor was it qualified as to audit
scope or accounting principles.
During the fiscal years ended March 31, 2021 and any subsequent
interim period through the date of dismissal, October 12, 2022, (i)
there were no “disagreements” (as described in Item 304(a)(1)(iv)
of Regulation S-K and the related instructions) between
the Company and WWC on any matter of accounting principles or
practices, financial statement disclosure or auditing scope or
procedures, which disagreements, if not resolved to WWC’s
satisfaction, would have caused WWC to make reference in connection
with WWC’s opinion to the subject matter of the disagreement; and
(ii) there were no “reportable events” as the term is
described in Item 304(a)(1)(v) of Regulation S-K.
We furnished a copy of the disclosures in this report to WWC and
have requested that WWC furnish us with a letter addressed to the
SEC stating whether such firm agrees with the above statements or,
if not, stating the respects in which it does not agree. We have
received the requested letter from WWC, and a copy of the letter is
filed with this Current Report on Form 8-K as Exhibit
16.1.
Engagement of New Independent Registered Public Accounting
Firm
On October 12, 2022, the Audit Committee approved the appointment
of OneStop Assurance PAC (“OneStop”) as the Company’s
independent registered public accounting firm to audit the
Company’s consolidated financial statements as of and for the
fiscal year ending March 31, 2022, effective October 28, 2022.
During the two most recent fiscal years and through October 28,
2022, the Company has not consulted with OneStop regarding
(1) any matter that was the subject of a disagreement or a
reportable event described in Items 304(a)(1)(iv) or (v),
respectively, or (2) any matter that was the subject of a
disagreement or a reportable event described in Items 304(a)(1)(iv)
or (v), respectively, of Regulation S-K.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
|
Akso
Health Group |
|
|
|
|
|
By: |
/s/
Yilin (Linda) Wang |
|
|
Name:
Yilin (Linda) Wang |
|
|
Title:
Chief Executive Officer |
|
|
|
Date:
November 1, 2022 |
|
|
Xiaobia Maimai (NASDAQ:HX)
Historical Stock Chart
From Apr 2023 to May 2023
Xiaobia Maimai (NASDAQ:HX)
Historical Stock Chart
From May 2022 to May 2023